Predictive Factors for Transition to Conversion Therapy in HCC Using Atezolizumab Plus Bevacizumab.

Liver InternationalEarly View LETTER TO THE EDITOR Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab Bing Chen, Bing Chen Department of Clinical Laboratory, Wenchang People's Hospital, Wenchang, Hainan, ChinaSearch for more papers by this authorBojie Huang, Corresponding Author Bojie Huang [email protected] orcid.org/0009-0002-9393-2239 Department of Clinical Laboratory, Affiliated Hospital of Hebei Engineering University, Handan, Hebei, China Correspondence Bojie Huang, Department of Clinical Laboratory, Affiliated Hospital of Hebei Engineering University, 81 Congtai Road, Handan 056002, Hebei, China. Email: [email protected]Search for more papers by this author Bing Chen, Bing Chen Department of Clinical Laboratory, Wenchang People's Hospital, Wenchang, Hainan, ChinaSearch for more papers by this authorBojie Huang, Corresponding Author Bojie Huang [email protected] orcid.org/0009-0002-9393-2239 Department of Clinical Laboratory, Affiliated Hospital of Hebei Engineering University, Handan, Hebei, China Correspondence Bojie Huang, Department of Clinical Laboratory, Affiliated Hospital of Hebei Engineering University, 81 Congtai Road, Handan 056002, Hebei, China. Email: [email protected]Search for more papers by this author First published: 08 May 2024 https://doi.org/10.1111/liv.15944 Handling Editor: Alejandro Forner. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Kikuchi T, Takeuchi Y, Nouso K, et al. Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab. Liver Int. 2024. PubMedWeb of Science®Google Scholar 2van Smeden M, Moons KG, de Groot JA, et al. Sample size for binary logistic prediction models: beyond events per variable criteria. Stat Methods Med Res. 2019; 28(8): 2455-2474. 10.1177/0962280218784726 PubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation